Elinzanetant is a non-hormonal, selective, dual neurokinin 1 (NK-1) and 3 (NK-3) receptor antagonist. On July 23, 2025, it was approved by Health Canada to treat moderate to severe vasomotor symptoms (VMS) associated with menopause. By blocking receptor signaling on kisspeptin/neurokinin B/dynorphin (KNDy) neurons, which are hyperactivated due to estrogen decline in menopause, elinzanetant modulates neuronal activity involved in thermo-regulation. Later the same year, it was approved in the US for the same indication. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Lynkuet, 2-(3, 5-BIS(TRIFLUOROMETHYL)PHENYL)-N-(4-(4-FLUORO-2-METHYLPHENYL)-6-((7S and 9AS)-7-. Its PubChem CID is 16063568.
Elinzanetant
| CAS No | 929046-33-3 |
|---|---|
| Molecular Formula | C33H35F7N4O3 |
| Molecular Weight | 668.6 g/mol |
| Synonyms | N-[6-[(7S,9aS)-7-(hydroxymethyl)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-4-(4-fluoro-2-methylphenyl)-3-pyridinyl]-2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethylpropanamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Elinzanetant is a non-hormonal, selective, dual neurokinin 1 (NK-1) and 3 (NK-3) receptor antagonist. On July 23, 2025, it was approved by Health Canada to treat moderate to severe vasomotor symptoms (VMS) associated with menopause.
The listed CAS number is 929046-33-3.
The listed molecular formula is C33H35F7N4O3.
The listed molecular weight is 668.6 g/mol.
N-[6-[(7S,9aS)-7-(hydroxymethyl)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-4-(4-fluoro-2-methylphenyl)-3-pyridinyl]-2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethylpropanamide.
The source lists Lynkuet, 2-(3, 5-BIS(TRIFLUOROMETHYL)PHENYL)-N-(4-(4-FLUORO-2-METHYLPHENYL)-6-((7S and 9AS)-7-.